KR20060089232A - 치환 벤자졸 및 ｒａｆ 키나제의 억제제로서 그들의 사용 - Google Patents
치환 벤자졸 및 ｒａｆ 키나제의 억제제로서 그들의 사용 Download PDFInfo
- Publication number
- KR20060089232A KR20060089232A KR1020067006470A KR20067006470A KR20060089232A KR 20060089232 A KR20060089232 A KR 20060089232A KR 1020067006470 A KR1020067006470 A KR 1020067006470A KR 20067006470 A KR20067006470 A KR 20067006470A KR 20060089232 A KR20060089232 A KR 20060089232A
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- substituted
- methyl
- amino
- unsubstituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 0 Bc1cc(NC(*2C)=Nc3c2ccc(Oc2cc(C(NC)=O)ncc2)c3)ccc1N Chemical compound Bc1cc(NC(*2C)=Nc3c2ccc(Oc2cc(C(NC)=O)ncc2)c3)ccc1N 0.000 description 5
- QLULGIRFKAWHOJ-UHFFFAOYSA-N OB(c1ccncc1)O Chemical compound OB(c1ccncc1)O QLULGIRFKAWHOJ-UHFFFAOYSA-N 0.000 description 2
- LGTOBOCIVPDCTA-UHFFFAOYSA-N Bc(c(C)c1)ccc1Nc1nc(C=C(C(C)C2)Oc3cc(CO)ncc3)c2[n]1C Chemical compound Bc(c(C)c1)ccc1Nc1nc(C=C(C(C)C2)Oc3cc(CO)ncc3)c2[n]1C LGTOBOCIVPDCTA-UHFFFAOYSA-N 0.000 description 1
- ODRLCTONCNSRBQ-UHFFFAOYSA-N CC(C)(C)OC(N(CC(N1C)=O)CC1=O)=O Chemical compound CC(C)(C)OC(N(CC(N1C)=O)CC1=O)=O ODRLCTONCNSRBQ-UHFFFAOYSA-N 0.000 description 1
- CJDYFMIDIQXELO-UHFFFAOYSA-N CC(C)(C)OC(N1CCN(C)CC1)=O Chemical compound CC(C)(C)OC(N1CCN(C)CC1)=O CJDYFMIDIQXELO-UHFFFAOYSA-N 0.000 description 1
- WMZHGAPKYJUAFH-UHFFFAOYSA-N CC(C)c1cc(Nc2nc(cc(cc3)Oc4ccnc(C(Nc5cc(C(C)(C)C)ccc5)=O)c4)c3[n]2C)ccc1 Chemical compound CC(C)c1cc(Nc2nc(cc(cc3)Oc4ccnc(C(Nc5cc(C(C)(C)C)ccc5)=O)c4)c3[n]2C)ccc1 WMZHGAPKYJUAFH-UHFFFAOYSA-N 0.000 description 1
- CLPZHEDSMNQBPP-UHFFFAOYSA-N CC1NC(C)CN(C)C1 Chemical compound CC1NC(C)CN(C)C1 CLPZHEDSMNQBPP-UHFFFAOYSA-N 0.000 description 1
- MIQPSMRKRPYFOB-UHFFFAOYSA-N CCN(CCO1)CC1/[O]=C1\N(C)CCCCC1 Chemical compound CCN(CCO1)CC1/[O]=C1\N(C)CCCCC1 MIQPSMRKRPYFOB-UHFFFAOYSA-N 0.000 description 1
- KWCVYUHZCVVARZ-UHFFFAOYSA-N CCc1cccc(NC(c2cc(Oc(cc3)cc4c3[n](C)c(Nc(cc3)ccc3Br)n4)ccn2)=O)c1 Chemical compound CCc1cccc(NC(c2cc(Oc(cc3)cc4c3[n](C)c(Nc(cc3)ccc3Br)n4)ccn2)=O)c1 KWCVYUHZCVVARZ-UHFFFAOYSA-N 0.000 description 1
- PREDVCVMQCMUDT-UHFFFAOYSA-N CN(C(CCC1N)=O)C1=O Chemical compound CN(C(CCC1N)=O)C1=O PREDVCVMQCMUDT-UHFFFAOYSA-N 0.000 description 1
- LAEXPJQUWCGDGC-UHFFFAOYSA-N CN(C(CNC1)=O)C1=O Chemical compound CN(C(CNC1)=O)C1=O LAEXPJQUWCGDGC-UHFFFAOYSA-N 0.000 description 1
- WRKUORHZZDCNMJ-UHFFFAOYSA-N CN(CC(N1CC(C(N2C)=O)OCC2=O)=O)CC1=O Chemical compound CN(CC(N1CC(C(N2C)=O)OCC2=O)=O)CC1=O WRKUORHZZDCNMJ-UHFFFAOYSA-N 0.000 description 1
- KOZRFVAOQYOQPI-UHFFFAOYSA-N CN(CC1)CCN1c(c(F)c1N)ccc1N Chemical compound CN(CC1)CCN1c(c(F)c1N)ccc1N KOZRFVAOQYOQPI-UHFFFAOYSA-N 0.000 description 1
- MJNGHBUJYPOPBE-UHFFFAOYSA-N CN1CC(CN2CCNCC2)OCC1 Chemical compound CN1CC(CN2CCNCC2)OCC1 MJNGHBUJYPOPBE-UHFFFAOYSA-N 0.000 description 1
- RXYPXQSKLGGKOL-UHFFFAOYSA-N CN1CCN(C)CC1 Chemical compound CN1CCN(C)CC1 RXYPXQSKLGGKOL-UHFFFAOYSA-N 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N CN1CCNCC1 Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- CDXLSMUOLYXICF-UHFFFAOYSA-N CNC(C(C1)[N+]([O-])=O)=CCC1Oc1ccnc(CO)c1 Chemical compound CNC(C(C1)[N+]([O-])=O)=CCC1Oc1ccnc(CO)c1 CDXLSMUOLYXICF-UHFFFAOYSA-N 0.000 description 1
- VTLQTHDJUGLYOA-UHFFFAOYSA-N CNC(c1cc(Oc(cc2)cc3c2[n](C)c(Nc2cc(-c4ccncc4)cc(F)c2OC)n3)ccn1)=O Chemical compound CNC(c1cc(Oc(cc2)cc3c2[n](C)c(Nc2cc(-c4ccncc4)cc(F)c2OC)n3)ccn1)=O VTLQTHDJUGLYOA-UHFFFAOYSA-N 0.000 description 1
- OJENAJAPLBHEKF-UHFFFAOYSA-N CNC(c1nccc(Oc(cc2)cc3c2[n](C)c(Nc2ccccc2I)n3)c1)=O Chemical compound CNC(c1nccc(Oc(cc2)cc3c2[n](C)c(Nc2ccccc2I)n3)c1)=O OJENAJAPLBHEKF-UHFFFAOYSA-N 0.000 description 1
- JOVTVEXJZXHXMT-UHFFFAOYSA-N CNC(c1nccc(Oc(cc2)cc3c2[n](C)c(Nc2ccccc2Sc2ccccc2)n3)c1)=O Chemical compound CNC(c1nccc(Oc(cc2)cc3c2[n](C)c(Nc2ccccc2Sc2ccccc2)n3)c1)=O JOVTVEXJZXHXMT-UHFFFAOYSA-N 0.000 description 1
- WDGQHUSWMGRXAC-NVMNQCDNSA-N CNc(c(N)c1)ccc1Oc1ccnc(/C=N\OC)c1 Chemical compound CNc(c(N)c1)ccc1Oc1ccnc(/C=N\OC)c1 WDGQHUSWMGRXAC-NVMNQCDNSA-N 0.000 description 1
- XQAZZUSVBUUVDS-UHFFFAOYSA-N CNc(c(N)c1)ccc1Oc1ccnc(CO)c1 Chemical compound CNc(c(N)c1)ccc1Oc1ccnc(CO)c1 XQAZZUSVBUUVDS-UHFFFAOYSA-N 0.000 description 1
- FEOLZZVRQKERDR-PXNMLYILSA-N CNc(ccc(Oc1cc(/C=N\O)ncc1)c1)c1[N+]([O-])=O Chemical compound CNc(ccc(Oc1cc(/C=N\O)ncc1)c1)c1[N+]([O-])=O FEOLZZVRQKERDR-PXNMLYILSA-N 0.000 description 1
- WTWNAWPQCMHEGE-UHFFFAOYSA-N CNc(ccc(Oc1cc(C=O)ncc1)c1)c1[N+]([O-])=O Chemical compound CNc(ccc(Oc1cc(C=O)ncc1)c1)c1[N+]([O-])=O WTWNAWPQCMHEGE-UHFFFAOYSA-N 0.000 description 1
- IRAJTRFSBJFFGT-UHFFFAOYSA-N COc(c(N)cc(Br)c1)c1F Chemical compound COc(c(N)cc(Br)c1)c1F IRAJTRFSBJFFGT-UHFFFAOYSA-N 0.000 description 1
- OZTHAIFCHYWJBM-UHFFFAOYSA-N C[O](c(c([N+]([O-])=O)cc(Br)c1)c1F)I Chemical compound C[O](c(c([N+]([O-])=O)cc(Br)c1)c1F)I OZTHAIFCHYWJBM-UHFFFAOYSA-N 0.000 description 1
- MIJTWRNGPSSNPA-UHFFFAOYSA-N C[n]1c(Nc(cc2)ccc2SC(F)(F)F)nc2cc(Oc3cc(C(NCCCN(CCC4)C4=O)=O)ncc3)ccc12 Chemical compound C[n]1c(Nc(cc2)ccc2SC(F)(F)F)nc2cc(Oc3cc(C(NCCCN(CCC4)C4=O)=O)ncc3)ccc12 MIJTWRNGPSSNPA-UHFFFAOYSA-N 0.000 description 1
- YZZQVNCYKMPCPO-ZRGSRPPYSA-N C[n]1c(Nc2ccc(C(F)(F)F)cc2)nc2c1ccc(Oc1cc(/C=N\O)ncc1)c2 Chemical compound C[n]1c(Nc2ccc(C(F)(F)F)cc2)nc2c1ccc(Oc1cc(/C=N\O)ncc1)c2 YZZQVNCYKMPCPO-ZRGSRPPYSA-N 0.000 description 1
- NMXMFJJNQWLAQV-UHFFFAOYSA-N C[n]1c(Nc2cccc(I)c2)nc2c1ccc(O)c2 Chemical compound C[n]1c(Nc2cccc(I)c2)nc2c1ccc(O)c2 NMXMFJJNQWLAQV-UHFFFAOYSA-N 0.000 description 1
- TUVXPFIKWFDPQB-UHFFFAOYSA-N Cc(c(-c1c[o]cc1)c1)ccc1[N+]([O-])=O Chemical compound Cc(c(-c1c[o]cc1)c1)ccc1[N+]([O-])=O TUVXPFIKWFDPQB-UHFFFAOYSA-N 0.000 description 1
- XFZFJQHXWJIBQV-UHFFFAOYSA-N Cc(c(Br)c1)ccc1[N+]([O-])=O Chemical compound Cc(c(Br)c1)ccc1[N+]([O-])=O XFZFJQHXWJIBQV-UHFFFAOYSA-N 0.000 description 1
- DIPGYZSCGXBTEU-UHFFFAOYSA-N Nc(c(F)c(cc1)F)c1[N+]([O-])=O Chemical compound Nc(c(F)c(cc1)F)c1[N+]([O-])=O DIPGYZSCGXBTEU-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
- C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
- C04B35/632—Organic additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Ceramic Engineering (AREA)
- Manufacturing & Machinery (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Materials Engineering (AREA)
- Structural Engineering (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/675,927 US8299108B2 (en) | 2002-03-29 | 2003-09-29 | Substituted benzazoles and methods of their use as inhibitors of raf kinase |
| US10/675,927 | 2003-09-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20060089232A true KR20060089232A (ko) | 2006-08-08 |
Family
ID=34422104
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020067006470A Ceased KR20060089232A (ko) | 2003-09-29 | 2004-09-29 | 치환 벤자졸 및 ｒａｆ 키나제의 억제제로서 그들의 사용 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US8299108B2 (https=) |
| EP (1) | EP1675584A1 (https=) |
| JP (1) | JP2007507428A (https=) |
| KR (1) | KR20060089232A (https=) |
| CN (1) | CN1913884A (https=) |
| AU (1) | AU2004277405A1 (https=) |
| BR (1) | BRPI0414908A (https=) |
| CA (1) | CA2539748A1 (https=) |
| EA (1) | EA011890B1 (https=) |
| IL (1) | IL174431A0 (https=) |
| MX (1) | MXPA06003435A (https=) |
| WO (1) | WO2005032548A1 (https=) |
| ZA (1) | ZA200603418B (https=) |
Families Citing this family (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7351834B1 (en) | 1999-01-13 | 2008-04-01 | Bayer Pharmaceuticals Corporation | ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| ATE538794T1 (de) | 1999-01-13 | 2012-01-15 | Bayer Healthcare Llc | Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer |
| MXPA04007832A (es) | 2002-02-11 | 2005-09-08 | Bayer Pharmaceuticals Corp | Aril-ureas con actividad inhibitoria de angiogenesis. |
| WO2003068229A1 (en) | 2002-02-11 | 2003-08-21 | Bayer Pharmaceuticals Corporation | Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors |
| NZ535985A (en) * | 2002-03-29 | 2007-04-27 | Chiron Corp | Substituted benzazoles and use thereof as RAF kinase inhibitors |
| US7557129B2 (en) | 2003-02-28 | 2009-07-07 | Bayer Healthcare Llc | Cyanopyridine derivatives useful in the treatment of cancer and other disorders |
| MXPA05012377A (es) | 2003-05-15 | 2006-05-25 | Arqule Inc | Derivados de imidazotiazoles e imidazoxazol como inhibidores de p38. |
| WO2004113274A2 (en) | 2003-05-20 | 2004-12-29 | Bayer Pharmaceuticals Corporation | Diaryl ureas with kinase inhibiting activity |
| EA010485B1 (ru) | 2003-07-23 | 2008-10-30 | Байер Фамэсьютиклс Копэрейшн | Производное n,n'-дифенилмочевины, фармацевтическая композиция (варианты) и способ лечения и предупреждения заболеваний и состояний с его использованием (варианты) |
| PT1682126E (pt) * | 2003-10-16 | 2009-10-02 | Novartis Vaccines & Diagnostic | Benzazois substituídos e sua utilização como inibidores da quinase raf |
| WO2006010082A1 (en) * | 2004-07-08 | 2006-01-26 | Arqule, Inc. | 1,4-disubstituted naphtalenes as inhibitors of p38 map kinase |
| JP2008517064A (ja) * | 2004-10-19 | 2008-05-22 | アークル インコーポレイテッド | Ｐ３８ｍａｐキナーゼのイミダゾオキサゾールおよびイミダゾチアゾール阻害剤の合成 |
| US7429608B2 (en) * | 2005-01-20 | 2008-09-30 | Amgen Inc. | Benzo[d]imidazol analogs as vanilloid receptor ligands and their use in treatments |
| TWI370820B (en) * | 2005-04-27 | 2012-08-21 | Takeda Pharmaceutical | Fused heterocyclic compounds |
| PE20070335A1 (es) | 2005-08-30 | 2007-04-21 | Novartis Ag | Benzimidazoles sustituidos y metodos para su preparacion |
| US7939528B2 (en) * | 2005-10-13 | 2011-05-10 | Glaxosmithkline Llc | Heterocycle compounds |
| CN102633783A (zh) | 2006-02-10 | 2012-08-15 | 转化技术制药公司 | 作为Aurora激酶抑制剂的苯并唑系衍生物、组合物和使用方法 |
| PE20080359A1 (es) | 2006-04-19 | 2008-06-06 | Novartis Ag | Compuestos de benzoxazol y benzotiazol 6-0-sustituidos y metodos de inhibicion de la senalizacion de csf-1r |
| EP2046292B1 (en) | 2006-07-21 | 2010-03-03 | Novartis AG | Formulations for benzimidazolyl pyridyl ethers |
| PE20080766A1 (es) * | 2006-08-30 | 2008-06-15 | Novartis Ag | Sales de benzimidazolil piridil eteres y formulaciones que las contienen |
| AU2008239179B2 (en) * | 2007-04-05 | 2011-02-24 | Daiichi Sankyo Company, Limited | Fused bicyclic heteroaryl derivatives |
| CL2008001626A1 (es) | 2007-06-05 | 2009-06-05 | Takeda Pharmaceuticals Co | Compuestos derivados de heterociclos fusionados, agente farmaceutico que los comprende y su uso en la profilaxis y tratamiento del cancer. |
| EP2181987B9 (en) | 2007-08-23 | 2014-09-03 | Takeda Pharmaceutical Company Limited | 2-Carbonylaminobenzothiazoles and their use for the prophylaxis and treatment of cancer |
| US8344135B2 (en) | 2007-08-29 | 2013-01-01 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
| AU2008305294B2 (en) | 2007-09-21 | 2012-11-29 | Array Biopharma Inc. | Pyridin-2 -yl-amino-1, 2, 4 -thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus |
| MX2010004246A (es) * | 2007-10-18 | 2010-04-30 | Novartis Ag | Inhibidores de csf-1r para el tratamiento de cancer y de enfermedades oseas. |
| US8697874B2 (en) * | 2008-12-01 | 2014-04-15 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
| JO3101B1 (ar) | 2008-12-02 | 2017-09-20 | Takeda Pharmaceuticals Co | مشتقات بنزوثيازول كعوامل مضادة للسرطان |
| CN102317293A (zh) * | 2008-12-05 | 2012-01-11 | 艾科尔公司 | Raf抑制剂及其用途 |
| KR20110123253A (ko) | 2009-03-05 | 2011-11-14 | 다이이찌 산쿄 가부시키가이샤 | 피리딘 유도체 |
| JP2013529968A (ja) | 2010-06-11 | 2013-07-25 | スミス アンド ネフュー インコーポレーテッド | 患者に適合した器具 |
| JP2013531687A (ja) | 2010-07-16 | 2013-08-08 | パーデュー、ファーマ、リミテッド、パートナーシップ | ナトリウムチャネル遮断剤としてのピリジン化合物 |
| EP2616441B1 (en) | 2010-09-17 | 2019-08-07 | Purdue Pharma L.P. | Pyridine compounds and the uses thereof |
| CN102276482A (zh) * | 2011-04-11 | 2011-12-14 | 常州大学 | 2-甲氧基-5-溴苯胺的制备方法 |
| US9408885B2 (en) | 2011-12-01 | 2016-08-09 | Vib Vzw | Combinations of therapeutic agents for treating melanoma |
| WO2013136170A1 (en) | 2012-03-16 | 2013-09-19 | Purdue Pharma L.P. | Substituted pyridines as sodium channel blockers |
| WO2014096941A1 (en) | 2012-12-20 | 2014-06-26 | Purdue Pharma L.P. | Cyclic sulfonamides as sodium channel blockers |
| US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
| CN103435554A (zh) * | 2013-09-06 | 2013-12-11 | 中国药科大学 | 2-苯氨基苯并咪唑类化合物及其用途 |
| WO2015041534A1 (en) | 2013-09-20 | 2015-03-26 | Stichting Het Nederlands Kanker Instituut | P90rsk in combination with raf/erk/mek |
| EP3046557A1 (en) | 2013-09-20 | 2016-07-27 | Stichting Het Nederlands Kanker Instituut | Rock in combination with mapk-pathway |
| US10730866B2 (en) | 2014-04-07 | 2020-08-04 | Purdue Pharma L.P. | Indole derivatives and use thereof |
| US20170027940A1 (en) | 2014-04-10 | 2017-02-02 | Stichting Het Nederlands Kanker Instituut | Method for treating cancer |
| WO2015178770A1 (en) | 2014-05-19 | 2015-11-26 | Stichting Het Nederlands Kanker Instituut | Compositions for cancer treatment |
| UY36294A (es) | 2014-09-12 | 2016-04-29 | Novartis Ag | Compuestos y composiciones como inhibidores de quinasa |
| WO2016100184A1 (en) | 2014-12-16 | 2016-06-23 | Forum Pharmaceuticals, Inc. | Geminal substituted quinuclidine amide compounds as agonists of alpha-7 nicotinic acetylcholine receptors |
| CN105949178B (zh) * | 2015-03-09 | 2020-05-26 | 西格莱(苏州)生物医药有限公司 | 一种苯并咪唑类化合物、其制备方法、中间体及应用 |
| MX2017016231A (es) | 2015-06-10 | 2018-11-29 | Axovant Sciences Gmbh | Compuestos de aminobencisoxazol como agonistas de receptores a7-nicotínicos de acetilcolina. |
| WO2017027600A1 (en) | 2015-08-12 | 2017-02-16 | Forum Pharmaceuticals, Inc. | GEMINAL SUBSTITUTED AMINOBENZISOXAZOLE COMPOUNDS AS AGONISTS OF α7-NICOTINIC ACETYLCHOLINE RECEPTORS |
| KR101770310B1 (ko) | 2015-08-24 | 2017-08-24 | 이화여자대학교 산학협력단 | 2-(페닐아미노)벤조[d]옥사졸-5-올 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 염증성 질환의 예방 또는 치료용 약학적 조성물 |
| US11028055B2 (en) * | 2015-11-30 | 2021-06-08 | Children's Medical Center Corporation | Compounds for treating proliferative diseases |
| AU2017329090B9 (en) | 2016-09-19 | 2019-09-05 | Novartis Ag | Therapeutic combinations comprising a RAF inhibitor and a ERK inhibitor |
| CN106674264A (zh) * | 2016-12-20 | 2017-05-17 | 苏州汉德创宏生化科技有限公司 | (2,2,2‑三氟乙氧基)苯硼酸类化合物的合成方法 |
| JP7341060B2 (ja) | 2017-02-10 | 2023-09-08 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | Ｍａｐｋ経路の活性化に関連付けられる癌の処置のための方法及び医薬組成物 |
| US11242332B2 (en) | 2017-03-15 | 2022-02-08 | Sumitomo Dainippon Pharma Co., Ltd. | Method for producing benzimidazole derivative |
| ES2952265T3 (es) | 2017-05-02 | 2023-10-30 | Novartis Ag | Terapia combinada que comprende un inhibidor de Raf y trametinib |
| JP7234201B2 (ja) * | 2017-07-12 | 2023-03-07 | ブリストル－マイヤーズ スクイブ カンパニー | 心不全の治療のためのｒｏｃｋの５員アミノヘテロ環および５，６－または６，６員二環式アミノヘテロ環の阻害剤 |
| US11339157B1 (en) | 2017-10-24 | 2022-05-24 | Bayer Aktiengesellschaft | 4H-pyrrolo[3,2-c]pyridin-4-one derivatives |
| EP3732285A1 (en) | 2017-12-28 | 2020-11-04 | Tract Pharmaceuticals, Inc. | Stem cell culture systems for columnar epithelial stem cells, and uses related thereto |
| WO2019156438A1 (en) * | 2018-02-07 | 2019-08-15 | Korea Research Institute Of Chemical Technology | Hetero ring-fused phenyl compounds for inhibiting tnik and medical uses thereof |
| JP2022500385A (ja) | 2018-09-10 | 2022-01-04 | ミラティ セラピューティクス， インコーポレイテッド | 組み合わせ療法 |
| WO2020097396A1 (en) | 2018-11-07 | 2020-05-14 | Dana-Farber Cancer Institute, Inc. | Benzimidazole derivatives and aza-benzimidazole derivatives as janus kinase 2 inhibitors and uses thereof |
| EP3877371A4 (en) | 2018-11-07 | 2022-07-27 | Dana-Farber Cancer Institute, Inc. | IMIDAZOPYRIDINE DERIVATIVES AND AZA-IMIDAZOPYRIDINE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF |
| WO2020097398A1 (en) | 2018-11-07 | 2020-05-14 | Dana-Farber Cancer Institute, Inc. | Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof |
| WO2020216773A1 (en) | 2019-04-24 | 2020-10-29 | Bayer Aktiengesellschaft | 4h-pyrrolo[3,2-c]pyridin-4-one compounds |
| GEAP202415804A (en) | 2019-04-24 | 2024-02-12 | Bayer Ag | 4h-pyrrolo[3,2-c]pyridin-4-one compounds |
| EP3958865B1 (en) | 2019-04-24 | 2025-12-10 | Bayer Aktiengesellschaft | 4h-pyrrolo[3,2-c]pyridin-4-one derivatives |
| ES3025633T3 (en) | 2019-05-13 | 2025-06-09 | Novartis Ag | New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer |
| WO2021198020A1 (en) | 2020-03-31 | 2021-10-07 | Bayer Aktiengesellschaft | 3-(anilino)-2-[3-(3-alkoxy-pyridin-4-yl]-1,5,6,7-tetrahydro-4h-pyrrolo[3,2-c]pyridin-4-one derivatives as egfr inhibitors for the treatment of cancer |
| CA3181537A1 (en) * | 2020-05-06 | 2021-11-11 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors |
| WO2022133098A2 (en) * | 2020-12-16 | 2022-06-23 | Ifm Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
| EP4267574B1 (en) | 2020-12-23 | 2025-04-23 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors |
| WO2023009708A1 (en) * | 2021-07-29 | 2023-02-02 | Ajax Therapeutics, Inc. | Heteroaryloxy triazolo- and imidazo-azines as jak2 inhibitors |
| TW202325289A (zh) | 2021-11-09 | 2023-07-01 | 美商雅捷可斯治療公司 | Ｊａｋ２抑制劑之形式及組合物 |
| JP7782035B2 (ja) | 2021-11-09 | 2025-12-08 | エイジャックス セラピューティクス， インコーポレイテッド | Ｊａｋ２阻害剤としての６－ヘテロアリールオキシベンゾイミダゾール及びアザベンゾイミダゾール |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4713698B2 (ja) | 1997-03-05 | 2011-06-29 | スージェン， インク． | 疎水性薬剤の処方 |
| GB9711650D0 (en) | 1997-06-05 | 1997-07-30 | Pfizer Ltd | Compounds useful in therapy |
| US6211177B1 (en) | 1998-11-24 | 2001-04-03 | Cell Pathways, Inc. | Method for treating neoplasia by exposure to substituted 2-aryl-benzimidazole derivatives |
| WO2000042012A1 (en) | 1999-01-13 | 2000-07-20 | Bayer Corporation | φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS |
| PL215901B1 (pl) | 1999-04-15 | 2014-02-28 | Bristol Myers Squibb Co | Cykliczny inhibitor bialkowych kinaz tyrozynowych, jego zastosowanie oraz kompozycja farmaceutyczna zawierajaca taki zwiazek |
| EP1218358B1 (en) | 1999-09-23 | 2006-09-13 | AstraZeneca AB | Therapeutic quinazoline compounds |
| ES2218391T3 (es) | 2000-03-06 | 2004-11-16 | Smithkline Beecham Plc | Derivados de imidazol como inhibidores de raf-cinasa. |
| US6642252B2 (en) | 2000-11-07 | 2003-11-04 | Bristol-Myers Squibb Company | Acid derivatives useful as serine protease inhibitors |
| AU2002232439A1 (en) | 2000-11-29 | 2002-06-11 | Glaxo Group Limited | Benzimidazole derivatives useful as tie-2 and/or vegfr-2 inhibitors |
| US20030009034A1 (en) | 2001-03-22 | 2003-01-09 | Neil Wishart | Transition metal mediated process |
| GB0112348D0 (en) | 2001-05-19 | 2001-07-11 | Smithkline Beecham Plc | Compounds |
| NZ535985A (en) * | 2002-03-29 | 2007-04-27 | Chiron Corp | Substituted benzazoles and use thereof as RAF kinase inhibitors |
| US7531553B2 (en) | 2003-03-21 | 2009-05-12 | Amgen Inc. | Heterocyclic compounds and methods of use |
| US7893096B2 (en) * | 2003-03-28 | 2011-02-22 | Novartis Vaccines And Diagnostics, Inc. | Use of small molecule compounds for immunopotentiation |
-
2003
- 2003-09-29 US US10/675,927 patent/US8299108B2/en not_active Expired - Fee Related
-
2004
- 2004-09-29 WO PCT/US2004/032161 patent/WO2005032548A1/en not_active Ceased
- 2004-09-29 AU AU2004277405A patent/AU2004277405A1/en not_active Abandoned
- 2004-09-29 KR KR1020067006470A patent/KR20060089232A/ko not_active Ceased
- 2004-09-29 BR BRPI0414908-4A patent/BRPI0414908A/pt not_active IP Right Cessation
- 2004-09-29 CN CNA2004800326778A patent/CN1913884A/zh active Pending
- 2004-09-29 EA EA200600689A patent/EA011890B1/ru not_active IP Right Cessation
- 2004-09-29 MX MXPA06003435A patent/MXPA06003435A/es not_active Application Discontinuation
- 2004-09-29 CA CA002539748A patent/CA2539748A1/en not_active Abandoned
- 2004-09-29 EP EP04789345A patent/EP1675584A1/en not_active Withdrawn
- 2004-09-29 JP JP2006528331A patent/JP2007507428A/ja not_active Withdrawn
-
2006
- 2006-03-21 IL IL174431A patent/IL174431A0/en unknown
- 2006-04-28 ZA ZA200603418A patent/ZA200603418B/en unknown
-
2012
- 2012-07-24 US US13/556,907 patent/US20120288501A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN1913884A (zh) | 2007-02-14 |
| BRPI0414908A (pt) | 2006-11-07 |
| US8299108B2 (en) | 2012-10-30 |
| IL174431A0 (en) | 2006-08-01 |
| US20040122237A1 (en) | 2004-06-24 |
| EA011890B1 (ru) | 2009-06-30 |
| JP2007507428A (ja) | 2007-03-29 |
| CA2539748A1 (en) | 2005-04-14 |
| ZA200603418B (en) | 2007-07-25 |
| EP1675584A1 (en) | 2006-07-05 |
| MXPA06003435A (es) | 2006-06-20 |
| EA200600689A1 (ru) | 2006-08-25 |
| AU2004277405A1 (en) | 2005-04-14 |
| US20120288501A1 (en) | 2012-11-15 |
| WO2005032548A1 (en) | 2005-04-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20060089232A (ko) | 치환 벤자졸 및 ｒａｆ 키나제의 억제제로서 그들의 사용 | |
| KR101071123B1 (ko) | 치환된 벤자졸 및 ｒａｆ 키나아제 저해제로서의 그들의이용 | |
| ES2327418T3 (es) | Benzazoles sustituidos y uso de los mismos como inhibidores de la quinasa raf. | |
| JP2007509059A (ja) | 癌の処置のためのＲａｆキナーゼのインヒビターとしての、２，６−二置換キナゾリン、キノキサリン、キノリンおよびイソキノリン | |
| HK1067945B (en) | Substituted benzazoles and use thereof as raf kinase inhibitors | |
| HK1078779B (en) | Substituted benzazoles and use thereof as raf kinase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20060403 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20090810 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20110919 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20120221 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20110919 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |